News Updates

More Articles Back to Article

Ironwood Pharma to purchase VectivBio for $1B

Ironwood Pharmaceuticals has unveiled plans to acquire VectivBio Holding, a Switzerland-based drug developer, in a deal worth approximately $1 billion, including the company's debt. The purchase will grant Ironwood access to apraglutide, VectivBio's lead drug that is being developed to treat short bowel syndrome with intestinal failure. MedCity News (5/23)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!